TNGX · Tango Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $62.38M | $42.07M | $36.53M | $24.86M | $7.66M | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $132.16M | $143.92M | $115.20M | $105.91M | $49.99M | - |
| SG&A | $41.51M | $43.75M | $35.50M | $30.02M | $9.87M | - |
| Total Operating Expenses | $173.67M | $187.66M | $150.70M | $135.93M | $59.86M | - |
| D&A | $2.28M | $2.50M | $2.42M | $1.61M | $718.0K | - |
| Operating Income | ($111.29M) | ($145.59M) | ($114.17M) | ($111.07M) | ($52.20M) | - |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $4.0K | $208.0K | $134.0K | $54.0K | $0 | - |
| Net Income | ($101.59M) | ($130.30M) | ($101.74M) | ($108.18M) | ($51.97M) | - |
| EPS - Basic | ($0.87) | ($1.19) | ($1.08) | ($0.94) | - | - |
| EPS - Diluted | ($0.87) | ($1.19) | ($1.08) | ($0.94) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $112.28M | $69.53M | $66.39M | $59.97M | $142.75M | $1.31M |
| Accounts Receivable | - | - | - | $2.00M | $2.00M | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $1.18M | $1.60M | $2.79M | $4.45M | $3.23M | - |
| Current Assets | $353.76M | $266.34M | $346.54M | $375.27M | $492.34M | $1.50M |
| Total Assets | $398.69M | $316.49M | $402.57M | $436.47M | $500.15M | $168.31M |
| Current Liabilities | $21.68M | $38.17M | $45.94M | $55.55M | $40.69M | $114.4K |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $52.51M | $116.97M | $149.46M | $186.99M | $155.41M | $5.95M |
| Stockholders' Equity | $346.18M | $199.52M | $253.11M | $249.48M | $344.75M | $5.00M |
| Retained Earnings | ($603.15M) | ($501.56M) | ($371.26M) | ($269.51M) | ($161.34M) | ($123.0K) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($138.89M) | ($131.50M) | ($117.98M) | ($109.08M) | $70.07M | - |
| Investing Cash Flow | ($40.87M) | $86.13M | $41.43M | $26.40M | ($145.47M) | - |
| Financing Cash Flow | $222.50M | $47.66M | $82.41M | $1.61M | $80.88M | - |
| CapEx | $1.05M | $754.0K | $1.53M | $7.69M | $1.11M | - |
| Free Cash Flow | ($139.93M) | ($132.25M) | ($119.51M) | ($116.77M) | $68.97M | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -178.4% | -346.1% | -312.6% | -446.8% | -681.8% | - |
| EBITDA margin | -174.7% | -340.1% | -306.0% | -440.3% | -672.4% | - |
| Net margin | -162.9% | -309.7% | -278.5% | -435.1% | -678.8% | - |
| Free cash flow margin | -224.3% | -314.4% | -327.2% | -469.7% | 900.8% | - |
| FCF / Net income | 1.38 | 1.01 | 1.17 | 1.08 | -1.33 | - |
| R&D / Revenue | 211.9% | 342.1% | 315.4% | 426.0% | 653.0% | - |
| SG&A / Revenue | 66.5% | 104.0% | 97.2% | 120.8% | 128.9% | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -25.5% | -41.2% | -25.3% | -24.8% | -10.4% | - |
| Return on equity | -29.3% | -65.3% | -40.2% | -43.4% | -15.1% | - |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 16.32 | 6.98 | 7.54 | 6.76 | 12.10 | 13.10 |
| Quick ratio | 16.32 | 6.98 | 7.54 | 6.76 | 12.10 | 13.10 |
| Cash ratio | 5.18 | 1.82 | 1.45 | 1.08 | 3.51 | 11.49 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.15 | 1.59 | 1.59 | 1.75 | 1.45 | 33.66 |
| Liabilities / Assets | 0.13 | 0.37 | 0.37 | 0.43 | 0.31 | 0.04 |
| Efficiency | ||||||
| Asset turnover | 0.16 | 0.13 | 0.09 | 0.06 | 0.02 | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | 29d | 95d | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 3.0x | 1.7x | 3.7x | 1.8x | - | - |
| P / S | 16.5x | 8.0x | 25.6x | 18.1x | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 48.3% | 15.2% | 46.9% | 224.7% | - | - |
| Revenue CAGR (3y) | 35.9% | 76.5% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 23.6% | -27.5% | -2.8% | -112.8% | - | - |
| Net income growth (YoY) | 22.0% | -28.1% | 5.9% | -108.1% | - | - |
| EPS growth (YoY) | 26.9% | -10.2% | -14.9% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -5.8% | -10.7% | -2.3% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 73.5% | -21.2% | 1.5% | -27.6% | 6794.9% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$62.38M totalCollaboration Revenue$62.38M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.37
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Tango Therapeutics against the 5 most active filers in the same SIC group.